Saturday , October 16 2021

Orchid Pharma shines on getting nod from USFDA for Risedronate Sodium Tablets

Orchid Pharma is currently trading at Rs. 4.00, up by 0.17 points or 4.44% from its previous closing of Rs. 3.83 on the BSE.

The scrip opened at Rs. 4.00 and has touched a high and low of Rs. 4.00 and Rs. 4.00 respectively. So far 600 shares were traded on the counter.

The BSE group ‘Z’ stock of face value Rs. 10 has touched a 52 week high of Rs. 10.50 on 22-Jun-2018 and a 52 week low of Rs. 3.04 on 14-Feb-2019.

Last one week high and low of the scrip stood at Rs 4.72 and Rs. 3.83 respectively. The current market cap of the company is Rs. 34.07 crore.

The promoters holding in the company stood at 26.68%, while Institutions and Non-Institutions held 4.52% and 68.80% respectively.

Orchid has received ANDA approval from United States Food and Drug Administration (USFDA) for Risedronate Sodium Tablets USP, 30 mg and 35 mg. Risedronate sodium tablets are a bisphosphonate indicated for the treatment and prevention of Osteoporosis.

Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients and finished dosage forms. It is also engaged in research of new drugs.

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'